Journals / Turkish Journal of Pharmaceutical Sciences / 2019 / Cilt: 16 - Sayı: 1

Development of a Discriminative and Biorelevant Dissolution Test Method for Atorvastatin/ Fenofibrate Combination with Appliance of Derivative Spectrophotometry

Türev Spektrofotometrik Yöntem ile Atorvastatin/Fenofibrat Kombinasyonunda Ayırıcı ve Biyouyumlu Çözünme Testi Metodunun Geliştirilmesi

Pages
62–68
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Hence the use of 0.5% w/v sodiumlauryl sulfate solution is justified.Conclusion: The dissolution method was validated (% relative standard deviation

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Nowadays, the market is flooded with combinations of drugs in various dosage forms, but there is a lack of official methods to quantifythem.
📊
Key Findings & Data:A single dissolution test method for the analysis of combined dosage form is preferred for simplification of quality control testing.Materials and Methods: If the developed dissolution medium mimics the biorelevant and discriminating dissolution procedure for drug productswith limited drug aqueous solubility it is a useful tool for qualitative forecasting of the in vivo behavior of formulations.Results: Dissolution profiles were evaluated for atorvastatin and fenofibrate in capsules, using a paddle-type United States Pharmacopeiadissolution apparatus in 900 mL of medium at 50 rpm and 37±0.5°C.
💡
Conclusion & Impact:Hence the use of 0.5% w/v sodiumlauryl sulfate solution is justified.Conclusion: The dissolution method was validated (% relative standard deviation
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: Nowadays, the market is flooded with combinations of drugs in various dosage forms, but there is a lack of official methods to quantifythem. A single dissolution test method for the analysis of combined dosage form is preferred for simplification of quality control testing.Materials and Methods: If the developed dissolution medium mimics the biorelevant and discriminating dissolution procedure for drug productswith limited drug aqueous solubility it is a useful tool for qualitative forecasting of the in vivo behavior of formulations.Results: Dissolution profiles were evaluated for atorvastatin and fenofibrate in capsules, using a paddle-type United States Pharmacopeiadissolution apparatus in 900 mL of medium at 50 rpm and 37±0.5°C. The best medium was 900 mL of 0.5% w/v sodium lauryl sulfate. Thecumulative % dissolution was more than 85% within 45 min for marketed tablets. The proposed dissolution test conditions have discriminativepower, dissimilarity factor (f1) values are low (12-16%), and similarity (f2) factor values are also low (45-48%). Hence the use of 0.5% w/v sodiumlauryl sulfate solution is justified.Conclusion: The dissolution method was validated (% relative standard deviation

Özet

Amaç: Günümüzde, çeşitli dozaj formlarında etkin madde kombinasyonlarına rağbet edilmektedir, ancak bunlardaki etkin maddeleri tayin etmek için farmakope yöntemleri bulunmamaktadır. Bu çalışmada, kombine dozaj formunun analizi için kalite kontrol testini sadeleştirmek amacıyla tek bir çözünme testi yöntemi tercih edilmiştir. Gereç ve Yöntemler: Suda çözünürlüğü sınırlı olan ilacın çözünme yöntemi için geliştirilen çözünme ortamı in vivo davranışlarının kalitatif tahmininde biyouyumlu bir yöntem olarak kullanışlı bulunmuştur. Bulgular: Atorvastatin ve fenofibrat içeren kapsüllerde çözünme profilleri, 37±0.5°C’de, 50 rpm ve 900 mL ortam içinde bir palet tipi Amerikan Farmakopesi çözünme cihazı ile değerlendirildi. En iyi ortam, 900 mL %0.5 a/h sodyum lauril sülfattır. Piyasadaki tabletler için kümülatif % çözünme, 45 dakika içinde %85’ten fazla olmuştur. Önerilen çözünme testi koşulları ayırt edici bir güce sahiptir, farklılık faktörü (f1 ) değerleri düşüktür (%12- 16) ve benzerlik (f2 ) faktör değerleri de düşüktür (%45-48). Bu nedenle, %0.5 w/v sodyum lauril sülfat çözeltisinin kullanımı uygundur. Sonuç: Çözünme yöntemi valide edilmiştir (% relatif standart sapma

🔖

Cite This Article

GURRALA, S., ANUMOLU, P. D., SATYA, S. C. V., POLISETTY, S. V., RAVINDRAN, A., ACHANTA, R. (2022). Development of a Discriminative and Biorelevant Dissolution Test Method for Atorvastatin/ Fenofibrate Combination with Appliance of Derivative Spectrophotometry. Turkish Journal of Pharmaceutical Sciences, Cilt: 16 - Sayı: 1, 62–68. https://ajindex.com/articles/613773

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Dressman J, Kramer J. Pharmaceutical dissolution testing (1st ed). London; Taylor and Francies; 2007:92-98
  2. Subrahmanyam CVS. Physical pharmaceutics (2nd ed). Delhi, India; Vallabh Prakashan; 2005:85-96. p
  3. Wang J, Flanagan DR. Fundamentals of dissolution (1st ed). New York; Academic Press; 2009:309-318
  4. Anumolu PD, Sunitha G, Bindu SH, Satheshbabu PR, Subrahmanyam CV. Development and validation of discriminating and biorelevant dissolution test for lornoxicam tablets. Indian J Pharm Sci. 2015;77:312-320
  5. Soni T, Nagda E, Tejal G, Chotai N. Development of discriminating method for dissolution of aceclofenac marketed formulations. Dissolution Technologies. 2008;15:31-34
  6. Dressman JB, Amidon GL, Reppas C, Shah VP. Dissolution testing as prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res. 1998;15:11-22
  7. Oliveira EFS, Aievedo RCP, Bonfilio R, Oliveira DB, Rebeiro GP, Araujo MB. Dissolution test optimization for meloxicam in the tablet pharmaceutical form. Braz J Pharm Sci. 2009;45:67-73
  8. He Z, Zhong D, Chen X, Liu X, Tang X, Zhao L. Development of a dissolution medium for nimodipine tablets based on bioavailabity evaluation. Eur J Pharm Sci. 2004;21:487-491
  9. Anumolu PD, Venkataraju Y, Gurrala S, Puvvadi S, Subrahmanyam CVS. Development of biorelevant and discriminating method for dissolution of efavirenz and its formulations. Asian J Pharm Clin Res. 2012;5:220-223
  10. Menegola J, Steppe M, Schapoval EE. Dissolution test for citalopram in tablets and comparison of in vitro dissolution profiles. Eur J Pharm Biopharm. 2007;67:524-530
  11. Anthony CM, David MO, Brian W. Clarke’s analysis of drugs and poisons (3rd ed). London; Pharmaceutical Press, 2004.654
  12. Indian pharmacopoeia (7th ed). Ghaziabad; The Indian Pharmacopoeia Commission; 2014:1099-1744
  13. Vignaduzzo SE, Castellano PM, Kaufman TS. Development and validation of a dissolution test for meloxicam and pridinol mesylate from combined tablet formulation. India J Pharm Sci. 2010;72:197-203
  14. Anumolu PD, Neeli S, Anuganti H, Ranganatham SBP, Satya SCV. Development of dissolution test method for a telmisartan/amlodipine besylate combination using synchronous derivative spectrofluorimetry. Braz J Pharm Sci. 2014;50:330-336
  15. Huang Z, Lozano R, Francis R, Aubry AF, Stecbeck A, Sociascia DO. Development of a single in vitro dissolution method for a combination trilayer tablet formulation of clopidogrel and pravastatin. Dissolution Technologie